CAS Number29094-61-9
SynonymsEINECS 249-427-6; Glican; Ozidia; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phényl}éthyl)-5-méthylpyrazine-2-carboxamide; Glipid; N-(2-{4-[(Cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methyl-2-pyrazinecarboxamide; k4024; N-(2-{4-[(Cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazin-2-carboxamid; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; exylurea; Glucotrol; Glipizide; MFCD00072159; N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide; Mindiab; Digrin; Glibenese; Glidiab; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; tk1320; Aldiab; Melizide
Molecular FormulaC21H27N5O4S
Molecular Weight445.54
Purity98%
Density1.4±0.1 g/cm3
Boiling Point676.0±65.0 °C at 760 mmHg
Melting Point208-209°C
Appearancesolid
EINECS249-427-6
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 29094-61-9 |
| Catalog No. | 2A-9010756 |
| Chinese Name | 格列吡嗪 |
| Synonyms | EINECS 249-427-6; Glican; Ozidia; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phényl}éthyl)-5-méthylpyrazine-2-carboxamide; Glipid; N-(2-{4-[(Cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methyl-2-pyrazinecarboxamide; k4024; N-(2-{4-[(Cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazin-2-carboxamid; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; exylurea; Glucotrol; Glipizide; MFCD00072159; N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide; Mindiab; Digrin; Glibenese; Glidiab; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; tk1320; Aldiab; Melizide |
| Molecular Formula | C21H27N5O4S |
| Molecular Weight | 445.54 |
| Purity | 98 |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 676.0±65.0 °C at 760 mmHg |
| Melting Point | 208-209°C |
| Appearance | solid |
| Water Solubility | methanol: 1.9 mg/mL |
| Storage Condition | Sealed in a cool, dry environment |
| Application | Glipizide acts on potassium channels and can be used for type 2 diabetes. |
| EINECS | 249-427-6 |
| HTC | 2935009090 |
| PubChem ID | 24277839 |
| MDL Number | MFCD00072159 |
| SMILES | Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3 |
| InChI | 1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28) |
| InChI Key | ZJJXGWJIGJFDTL-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/10756_1_29094_61_9.pdf |
| Bioactivity | Glipizide(K 4024; CP 2872) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.Target: Potassium ChannelGlipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Mechanism of action is produced by blocking potassium channels in the beta cells of the islets of Langerhans. By partially blocking the potassium channels, the cell remains depolarized, increasing the time the cell spends in the calcium release stage, which results in signaling leading to calcium influx. The increase in calcium will initiate more insulin release from each beta cell. Sulfonylureas may also cause the decrease of serum glucagon and potentiate the action of insulin at the extrapancreatic tissues [1, 2]. Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel Research Areas >> Metabolic Disease References [1]. Chowdary, K.P. and Y.S. Rao, Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech, 2003. 4(3): p. E39. [2]. Rao, N.G., et al., Suicide by combined insulin and glipizide overdose in a non-insulin dependent diabetes mellitus physician: a case report. Med Sci Law, 2006. 46(3): p. 263-9. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 676.0±65.0 °C at 760 mmHg Melting Point 208-209°C Molecular Formula C21H27N5O4S Molecular Weight 445.535 Flash Point 362.6±34.3 °C Exact Mass 445.178375 PSA 138.53000 LogP 3.37 Vapour Pressure 0.0±2.2 mmHg at 25°C Index of Refraction 1.654 InChIKey ZJJXGWJIGJFDTL-UHFFFAOYSA-N SMILES Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1 Storage condition -20°C Freezer Water Solubility methanol: 1.9 mg/mL |
| Use of | Glipizide(K 4024; CP 2872) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.Target: Potassium ChannelGlipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Mechanism of action is produced by blocking potassium channels in the beta cells of the islets of Langerhans. By partially blocking the potassium channels, the cell remains depolarized, increasing the time the cell spends in the calcium release stage, which results in signaling leading to calcium influx. The increase in calcium will initiate more insulin release from each beta cell. Sulfonylureas may also cause the decrease of serum glucagon and potentiate the action of insulin at the extrapancreatic tissues [1, 2]. Properties Articles22 Name glipizide Synonym More Synonyms Glipizide Biological Activity Description Glipizide(K 4024; CP 2872) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.Target: Potassium ChannelGlipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Mechanism of action is produced by blocking potassium channels in the beta cells of the islets of Langerhans. By partially blocking the potassium channels, the cell remains depolarized, increasing the time the cell spends in the calcium release stage, which results in signaling leading to calcium influx. The increase in calcium will initiate more insulin release from each beta cell. Sulfonylureas may also cause the decrease of serum glucagon and potentiate the action of insulin at the extrapancreatic tissues [1, 2]. Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel Research Areas >> Metabolic Disease References [1]. Chowdary, K.P. and Y.S. Rao, Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech, 2003. 4(3): p. E39. [2]. Rao, N.G., et al., Suicide by combined insulin and glipizide overdose in a non-insulin dependent diabetes mellitus physician: a case report. Med Sci Law, 2006. 46(3): p. 263-9. Chemical & Physical Properties Molecular Formula C21H27N5O4S Exact Mass 445.178375 PSA 138.53000 Index of Refraction 1.654 InChIKey ZJJXGWJIGJFDTL-UHFFFAOYSA-N |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Gemifloxacin | 175463-14-6 | 2A-9010708 |
| Gentamicin B | 36889-15-3 | 2A-9010715 |
| Gestodene | 60282-87-3 | 2A-9010720 |
| Glibenclamide | 10238-21-8 | 2A-9010753 |
| Glimepiride | 93479-97-1 | 2A-0202308 |
| Granisetron | 109889-09-0 | 2A-9010779 |
| Hydrocortisone | 50-23-7 | 2A-9010867 |
| Hydroxychloroquine sulfate | 747-36-4 | 2A-9010870 |
| Hydroxyprogesterone acetate | 302-23-8 | 2A-9010871 |
| Hydroxyprogesterone caproate | 630-56-8 | 2A-9010872 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS